Posted by Michael Wonder on 19 Oct 2023
European Commission approves Adcetris (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30 positive stage III Hodgkin lymphoma in combination with AVD
18 October 2023 - Approval based on updated positive overall survival results from the Phase 3 ECHELON-1 study for stage III & IV Hodgkin lymphoma.
Takeda today announced that the European Commission approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine to treat adult patients with previously untreated CD30 positive Stage III Hodgkin lymphoma.
